Literature DB >> 2825177

Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.

B D Walker1, M Kowalski, W C Goh, K Kozarsky, M Krieger, C Rosen, L Rohrschneider, W A Haseltine, J Sodroski.   

Abstract

Castanospermine (1,6,7,8-tetrahydroxyoctahydroindolizine) is a plant alkaloid that modifies glycosylation by inhibiting alpha-glucosidase I. Castanospermine is shown to inhibit syncytium formation induced by the envelope glycoprotein of the human immunodeficiency virus and to inhibit viral replication. The decrease in syncytium formation in the presence of castanospermine can be attributed to inhibition of processing of the envelope precursor protein gp160, with resultant decreased cell surface expression of the mature envelope glycoprotein gp120. In addition, castanospermine may cause defects in steps involved in membrane fusion after binding of CD4 antigen. The antiviral effects of castanospermine may be due to modifications of the envelope glycoprotein that affect the ability of the virus to enter cells after attachment to the CD4 cell receptor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825177      PMCID: PMC299490          DOI: 10.1073/pnas.84.22.8120

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

2.  Construction of recombinant murine retroviruses that express the human T-cell leukemia virus type II and human T-cell lymphotropic virus type III trans activator genes.

Authors:  C A Rosen; J G Sodroski; K Campbell; W A Haseltine
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

3.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

4.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

5.  Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

Authors:  F D Veronese; A L DeVico; T D Copeland; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

6.  Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells.

Authors:  E G Sandstrom; R T Schooley; D D Ho; R Byington; M G Sarngadharan; M E MacLane; M Essex; R C Gallo; M S Hirsch
Journal:  Transfusion       Date:  1985 Jul-Aug       Impact factor: 3.157

7.  Castanospermine inhibits alpha-glucosidase activities and alters glycogen distribution in animals.

Authors:  R Saul; J J Ghidoni; R J Molyneux; A D Elbein
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

8.  HTLV-III in the semen and blood of a healthy homosexual man.

Authors:  D D Ho; R T Schooley; T R Rota; J C Kaplan; T Flynn; S Z Salahuddin; M A Gonda; M S Hirsch
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

9.  Functional expression of the polymeric immunoglobulin receptor from cloned cDNA in fibroblasts.

Authors:  D L Deitcher; M R Neutra; K E Mostov
Journal:  J Cell Biol       Date:  1986-03       Impact factor: 10.539

10.  Unusual forms of low density lipoprotein receptors in hamster cell mutants with defects in the receptor structural gene.

Authors:  K F Kozarsky; H A Brush; M Krieger
Journal:  J Cell Biol       Date:  1986-05       Impact factor: 10.539

View more
  73 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.

Authors:  W R Lee; W J Syu; B Du; M Matsuda; S Tan; A Wolf; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Evaluation of the antiviral effect of new compounds by using cellular cultures.

Authors:  F Dianzani; G Antonelli
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

4.  HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.

Authors:  Thijs van Montfort; Dirk Eggink; Maikel Boot; Michael Tuen; Catarina E Hioe; Ben Berkhout; Rogier W Sanders
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

Review 5.  Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships.

Authors:  John F Cipollo; Lisa M Parsons
Journal:  Mass Spectrom Rev       Date:  2020-04-29       Impact factor: 10.946

6.  Aminosugar derivatives as potential anti-human immunodeficiency virus agents.

Authors:  A Karpas; G W Fleet; R A Dwek; S Petursson; S K Namgoong; N G Ramsden; G S Jacob; T W Rademacher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1.

Authors:  D C Montefiori; W E Robinson; W M Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.

Authors:  R G Geissler; J Muth; A Maurer; U Mentzel; M Mag; J W Engels; D Hoelzer; A Ganser
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

9.  The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.

Authors:  P B Fischer; M Collin; G B Karlsson; W James; T D Butters; S J Davis; S Gordon; R A Dwek; F M Platt
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Processing of the glycoprotein of feline immunodeficiency virus: effect of inhibitors of glycosylation.

Authors:  E B Stephens; E Monck; K Reppas; E J Butfiloski
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.